Lead Product(s): SAN711
Therapeutic Area: Neurology Product Name: SAN711
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination November 05, 2020
The termination of the GABAa5 program provides Saniona with rights to a portfolio of more than 800 molecules; the company intends to evaluate their applicability in rare diseases.